phentermine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anorexics 2140 122-09-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • phentermine
  • duromine
  • normephentermine
  • phentermine hydrochloride
  • phentermine HCl
  • phentermine resin complex
A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
  • Molecular weight: 149.24
  • Formula: C10H15N
  • CLOGP: 2.14
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 26.02
  • ALOGS: -2.29
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.19 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ

Approvals:

DateAgencyCompanyOrphan
May 4, 1959 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cholecystitis chronic 160.48 16.90 58 6077 10441 46669486
Injury 88.72 16.90 61 6074 43966 46635961
Angle closure glaucoma 74.24 16.90 22 6113 2117 46677810
Gallbladder disorder 73.82 16.90 39 6096 17459 46662468
Anxiety 67.47 16.90 100 6035 181857 46498070
Phospholipidosis 59.79 16.90 10 6125 61 46679866
Emotional distress 58.21 16.90 41 6094 30666 46649261
Carotid artery dissection 56.60 16.90 11 6124 169 46679758
Arteriospasm coronary 55.28 16.90 20 6115 3601 46676326
Drug abuse 48.07 16.90 50 6085 63358 46616569
Cholelithiasis 47.70 16.90 40 6095 38641 46641286
Subarachnoid haemorrhage 41.83 16.90 23 6112 11130 46668797
Pregnancy 39.67 16.90 31 6104 27106 46652821
Encephalomalacia 30.36 16.90 8 6127 500 46679427
Deep vein thrombosis 29.69 16.90 44 6091 79729 46600198
Spinal cord infarction 29.39 16.90 7 6128 289 46679638
Psoriasis 27.32 16.90 42 6093 78562 46601365
Stress cardiomyopathy 26.32 16.90 15 6120 7769 46672158
Depression 25.82 16.90 64 6071 170040 46509887
Paraesthesia 25.50 16.90 51 6084 117386 46562541
Colitis ischaemic 25.13 16.90 16 6119 10116 46669811
Renal vein thrombosis 24.27 16.90 6 6129 290 46679637
Biliary dyskinesia 23.49 16.90 10 6125 2763 46677164
Pain 22.22 16.90 122 6013 476826 46203101
Suicidal ideation 20.82 16.90 31 6104 56351 46623576
Pneumonia 20.57 16.90 12 6123 376308 46303619
Anhedonia 20.03 16.90 14 6121 10321 46669606
Device dislocation 17.96 16.90 18 6117 21784 46658143

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 54.10 27.53 32 835 82040 29869571

Pharmacologic Action:

SourceCodeDescription
ATC A08AA01 ALIMENTARY TRACT AND METABOLISM
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
Centrally acting antiobesity products
FDA PE N0000175372 Appetite Suppression
FDA EPC N0000175423 Sympathomimetic Amine Anorectic
FDA PE N0000175651 Increased Sympathetic Activity
MeSH PA D018663 Adrenergic Agents
MeSH PA D019440 Anti-Obesity Agents
MeSH PA D001067 Appetite Depressants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013566 Sympathomimetics
CHEBI has role CHEBI:35337 analeptic drug
CHEBI has role CHEBI:35470 cns agent
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:37962 adrenergic neuron agents
CHEBI has role CHEBI:48560 dopamine agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Low blood pressure indication 45007003
Obesity indication 414916001 DOID:9970
Prevention of Hypotension During Spinal Anesthesia indication
Hypotension Secondary to Spinal Anesthesia indication
Heart valve disorder contraindication 368009 DOID:4079
Alcoholism contraindication 7200002
Glaucoma contraindication 23986001 DOID:1686
Feeling agitated contraindication 24199005
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Mild pre-eclampsia contraindication 41114007
Conduction disorder of the heart contraindication 44808001
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Pulmonary hypertension contraindication 70995007 DOID:6432
Secondary glaucoma contraindication 95717004
Angina pectoris contraindication 194828000
Edema contraindication 267038008
Syncope contraindication 271594007
Arteriosclerosis obliterans contraindication 361133006 DOID:5160
Hypertensive urgency contraindication 443482000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.92 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter INHIBITOR WOMBAT-PK CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 5.80 WOMBAT-PK

External reference:

IDSource
4019891 VUID
N0000147976 NUI
D05458 KEGG_DRUG
1197-21-3 SECONDARY_CAS_RN
4018166 VANDF
4018167 VANDF
4019891 VANDF
C0013326 UMLSCUI
CHEBI:8080 CHEBI
CHEMBL1574 ChEMBL_ID
CHEMBL1200912 ChEMBL_ID
D010645 MESH_DESCRIPTOR_UI
DB00191 DRUGBANK_ID
4771 PUBCHEM_CID
7269 IUPHAR_LIGAND_ID
1064 INN_ID
C045TQL4WP UNII
221138 RXNORM
1294 MMSL
41147 MMSL
5278 MMSL
5279 MMSL
d00806 MMSL
001864 NDDF
001865 NDDF
001866 NDDF
373343009 SNOMEDCT_US
426428004 SNOMEDCT_US
53480001 SNOMEDCT_US
6394006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
phentermine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-0644 CAPSULE 15 mg ORAL ANDA 29 sections
phentermine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-0647 CAPSULE 30 mg ORAL ANDA 29 sections
phentermine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-5000 CAPSULE 30 mg ORAL ANDA 29 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-0597 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1308 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1310 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine ResinER HUMAN PRESCRIPTION DRUG LABEL 1 0527-1366 CAPSULE, EXTENDED RELEASE 30 mg ORAL ANDA 26 sections
Phentermine ResinER HUMAN PRESCRIPTION DRUG LABEL 1 0527-1398 CAPSULE, EXTENDED RELEASE 15 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1438 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1445 TABLET 37.50 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1742 CAPSULE 15 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1743 CAPSULE 37.50 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-098 CAPSULE 30 mg ORAL ANDA 26 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-099 CAPSULE 15 mg ORAL ANDA 9 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-116 TABLET 37.50 mg ORAL ANDA 9 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-552 TABLET 30 mg ORAL ANDA 31 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-592 CAPSULE 37.50 mg ORAL ANDA 9 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-593 CAPSULE 30 mg ORAL ANDA 19 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-602 TABLET 37.50 mg ORAL ANDA 19 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-620 CAPSULE 30 mg ORAL ANDA 9 sections
LOMAIRA HUMAN PRESCRIPTION DRUG LABEL 1 10702-001 TABLET 8 mg ORAL ANDA 17 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-025 TABLET 37.50 mg ORAL ANDA 25 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-025 TABLET 37.50 mg ORAL ANDA 25 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-026 CAPSULE 15 mg ORAL ANDA 29 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-027 CAPSULE 30 mg ORAL ANDA 29 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-028 CAPSULE 30 mg ORAL ANDA 29 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-029 CAPSULE 37.50 mg ORAL ANDA 25 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-029 CAPSULE 37.50 mg ORAL ANDA 25 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-067 TABLET 8 mg ORAL ANDA 17 sections
Phentermine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 11534-157 CAPSULE 15 mg ORAL ANDA 28 sections